PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy

BACKGROUND: Molecular biomarkers that might help to distinguish between more aggressive and clinically insignificant prostate cancers (PCa) are still urgently needed. Aberrant DNA methylation as a common molecular alteration in PCa seems to be a promising source for such biomarkers. In this study, P...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Epigenetics
Egile Nagusiak: Holmes, Emily Eva, Goltz, Diane, Sailer, Verena, Jung, Maria, Meller, Sebastian, Uhl, Barbara, Dietrich, Jörn, Röhler, Magda, Ellinger, Jörg, Kristiansen, Glen, Dietrich, Dimo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2016
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5037587/
https://ncbi.nlm.nih.gov/pubmed/27708722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-016-0270-x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak